ReviewProtein & cell2016
The role of galectin-4 in physiology and diseases.
Review in Protein & cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 99 citations in OpenAlex.
- Proteomic Profile After Intervention With Eplerenone Among Persons With HIV.Open forum infectious diseases · 2026Trial
- A glycosaminoglycan microarray identifies galectin-4 binding to sulfated glycosaminoglycans.Biochemistry and biophysics reports · 2026Article
- Hepatic LGALS4 Alleviates Diet-Induced Steatosis by Promoting AMPK-Dependent Fatty Acid Oxidation.Diabetes, obesity & metabolism · 2026Article
- The Galectin Family in Colorectal Cancer: Integrating Molecular Mechanisms with Diagnostic, Prognostic, and Therapeutic Perspectives.Biomedicines · 2026Review
- Astragaloside II suppresses colorectal cancer progression by upregulating LGALS4 expression.Journal of molecular histology · 2026Article
- Cardiovascular peptide markers are associated with age-related macular degeneration in the Bialystok PLUS general population cohort.Scientific reports · 2026Article
- Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation.Signal transduction and targeted therapy · 2026Review
- Dendrobium officinale Kimura et Migo regulates the proliferation and migration of colon adenocarcinoma via LGALS4.Molecular diversity · 2026Article
- Galectin-4 contributes to the maintenance of expression and activation of multiple receptor-type kinases involved in peritoneal metastasis.Scientific reports · 2026Article
- Methanol Extract fromAntioxidants (Basel, Switzerland) · 2025Article
- Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis.International journal of molecular sciences · 2025Article
- Association of Elevated Galectin-4 Concentrations with Obesity, Diabetes, and Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Inhibitory Effect of Fucoidan Analogs on Highly Metastatic Gastric Cancer Cells via Galectin-4 Inhibition.International journal of molecular sciences · 2025Article
- Galectin-4 potentiates CD8+ T cell immunity by enhancing MHC-I expression on dendritic cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Review
- Linear and non-linear proteome-wide association studies provide novel insight into venous thromboembolism.Nature communications · 2025Article
- Exploring the impact of galectins on liver cancer: From immunopathogenesis to potential targets.World journal of gastroenterology · 2025Review
- Proteomic Profile of Ischemic Heart Disease in Heart Failure: A Community Study.Mayo Clinic proceedings · 2025Article
- Analysis of Molecular Genetic Variants of Lgals4 in Esophageal Cancer: A Preliminary Report.Biochemical genetics · 2025Article
- Galectins and Liver Diseases.International journal of molecular sciences · 2025Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectin-4, a tandem repeat member of the β-galactoside-binding proteins, possesses two carbohydrate-recognition domains (CRD) in a single peptide chain. This lectin is mostly expressed in epithelial cells of the intestinal tract and secreted to the extracellular. The two domains have 40% similarity in amino acid sequence, but distinctly binding to various ligands. Just because the two domains bind to different ligands simultaneously, galectin-4 can be a crosslinker and crucial regulator in a large number of biological processes. Recent evidence shows that galectin-4 plays an important role in lipid raft stabilization, protein apical trafficking, cell adhesion, wound healing, intestinal inflammation, tumor progression, etc. This article reviews the physiological and pathological features of galectin-4 and its important role in such processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.